ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cholestatic liver disease (CLD) is characterized by inflammatory amplification, hepatic stellate cell activation and collagen deposition. Luteolin is a natural flavonoid with reported anti-inflammatory and anti-fibrotic activities. Here, network pharmacology, molecular docking and experimental analyses were integrated to examine the effects of luteolin in CLD, with a focus on PI3K/Akt/GSK-3β-associated signalling. Target prediction identified 181 putative luteolin targets and 4,403 CLD-related targets, with 88 overlapping genes. In a bile duct ligation (BDL) rat model, luteolin treatment was associated with lower serum injury indices, reduced histopathological damage, decreased collagen deposition and lower fibrosis-related readouts. Experimental analyses further showed that luteolin treatment was accompanied by lower phosphorylation-associated readouts along the PI3K/Akt/GSK-3β axis. Together, these findings support an association between luteolin treatment and attenuation of cholestatic liver injury and fibrosis, within a multi-target signalling context that includes PI3K/Akt/GSK-3β.
Indexed as
Identifiers
42331983What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.